Bexarotene activates type 1 antigen presenting cells, increases tumor infiltrating CD8 T-cells, and augments the anti-tumor activity of chemotherapy in breast cancer

被引：1
|
作者：
Stanton, Sasha Elizabeth
Gad, Ekram
Corulli-Rastetter, Lauren R.
Disis, Mary L.
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-3687
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3687
引用
收藏
页数：2
相关论文
共 50 条
  • [41] New insights on anti-tumor immunity of CD8+ T cells: cancer stem cells, tumor immune microenvironment and immunotherapy
    Lin, Yibin
    Song, Yifu
    Zhang, Yaochuan
    Li, Xiaodong
    Kan, Liang
    Han, Sheng
    JOURNAL OF TRANSLATIONAL MEDICINE, 2025, 23 (01)
  • [42] Inhibition of dopamine receptor D3 signaling in dendritic cells increases antigen cross-presentation to CD8+ T-cells favoring anti-tumor immunity
    Figueroa, Claudio
    Galvez-Cancino, Felipe
    Oyarce, Cesar
    Contreras, Francisco
    Prado, Carolina
    Valeria, Catalina
    Cruz, Sebastian
    Lladser, Alvaro
    Pacheco, Rodrigo
    JOURNAL OF NEUROIMMUNOLOGY, 2017, 303 : 99 - 107
  • [43] The opposite effect of tumor-infiltrating natural killer cells on in vivo priming of tumor-specific CD8(+) T cells and CD4(+) T cells
    Terao, H
    Harada, M
    Kurosawa, S
    Shinomiya, Y
    Ito, O
    Tamada, K
    Takenoyama, M
    Nomoto, K
    IMMUNOBIOLOGY, 1996, 195 (02) : 172 - 186
  • [44] EcSOD increases the anti-tumor efficacy of heparanase inhibitors in breast cancer cells
    Teoh, Melissa L. T.
    Oberley, Larrv W.
    FREE RADICAL BIOLOGY AND MEDICINE, 2007, 43 : S61 - S61
  • [45] Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model
    Bruno, Tullia C.
    Rothwell, Cristin
    Grosso, Joseph F.
    Getnet, Derese
    Yen, Hung Rong
    Durham, Nicholas M.
    Netto, George
    Pardoll, Drew M.
    Drake, Charles G.
    PROSTATE, 2012, 72 (05): : 514 - 522
  • [46] Type 1 CD8~+ T Cells are Superior to Type 2 CD8~+ T Cells in Tumor Immunotherapy due to Their Efficient Cytotoxicity,Prolonged Survival and Type 1 Immune Modulation
    Terence Moyana
    Jicheng Yang
    Jim Xiang
    Cellular&MolecularImmunology, 2007, (04) : 277 - 285
  • [47] Combination of agonist anti-OX40 therapy with CTLA-4 blockade augments anti-tumor effector CD4 and CD8 T cells
    Redmond, William
    Linch, Stefanie
    Kasiewicz, Melissa
    JOURNAL OF IMMUNOLOGY, 2013, 190
  • [48] The Prognostic Role of Tumor-infiltrating CD4 and CD8 T Lymphocytes in Breast Cancer
    Matkowski, Rafal
    Gisterek, Iwona
    Halon, Agnieszka
    Lacko, Aleksandra
    Szewczyk, Krzysztof
    Staszek, Urszula
    Pudelko, Marek
    Szynglarewicz, Bartlomiej
    Szelachowska, Jolanta
    Zolnierek, Andrzej
    Kornafel, Jan
    ANTICANCER RESEARCH, 2009, 29 (07) : 2445 - 2451
  • [49] Self-tumor-antigen-specific CD8 T cells were suppressed by regulatory T cells
    Maeda, Yuka
    Nishikawa, Hiroyoshi
    Sakaguchi, Shimon
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
  • [50] RECRUITMENT OF HOST CD8(+) T-CELLS BY TUMOR-INFILTRATING LYMPHOCYTES AND RECOMBINANT INTERLEUKIN-2 DURING ADOPTIVE IMMUNOTHERAPY OF CANCER
    BURGER, UL
    CHANG, MP
    GOEDEGEBUURE, PS
    EBERLEIN, TJ
    SURGERY, 1995, 117 (03) : 325 - 333
12345